Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 57 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Focal radiation therapy (RT) Clear all
Recruiting Phase 2 Interventional

Embryonal Tumor With Multilayered Rosettes

NCT06861244
View directory record Official record
Conditions
Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos
Interventions
Radiotherapy (RT), Chemotherapy Drug, Cancer - Physician's Choice, Non-Investigational Surgical Resection, Temozolomide, Tumor Tissue Sample, Blood Sample, Cerebrospinal Fluid (CSF) Sample
Radiation · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
8
States / cities
Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 17, 2026, 4:13 AM EDT
Completed Not applicable Interventional

TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck

NCT03729518
View directory record Official record
Conditions
Oropharyngeal Cancer, Squamous Cell Carcinoma, Human Papilloma Virus
Interventions
Radiation Therapy (IMRT or IMPT)
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 17, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma

NCT00200161
View directory record Official record
Conditions
Glioblastoma, Gliomas
Interventions
Temozolomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Sep 17, 2026, 4:13 AM EDT
Completed Phase 2 Interventional

Proton Craniospinal Radiation Therapy vs. Partial Photon Radiation Therapy for Leptomeningeal Metastasis From Solid Tumors

NCT04343573
View directory record Official record
Conditions
Leptomeningeal Metastases
Interventions
Involved-field Photon Radiation Therapy, Proton Craniospinal Irradiation (CSI), Neurocognitive Assessment, MDASI-BT and MDASI-SP
Radiation · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 99 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 17, 2026, 4:13 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

NCT00602667
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
Induction Chemotherapy, Low-Risk Therapy, High-Risk Therapy, Intermediate-Risk Therapy
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 5 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2029
U.S. locations
5
States / cities
Palo Alto, California • San Diego, California • Saint Paul, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 17, 2026, 4:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer

NCT00193128
View directory record Official record
Conditions
Esophagus Cancer
Interventions
Oxaliplatin, Docetaxel, Capecitabine, Radiation therapy
Drug · Radiation
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
7
States / cities
Beverly Hills, California • Jacksonville, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Sep 17, 2026, 4:13 AM EDT
Active, not recruiting Phase 2 Interventional

Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma

NCT01864109
View directory record Official record
Conditions
Newly Diagnosed Ewing Sarcoma
Interventions
Cyclophosphamide, Doxorubicin, Vincristine, Ifosfamide, Etoposide, Surgery, Radiation Therapy*, Temozolomide, Irinotecan, Mesna, Dexrazoxane, G-CSF
Drug · Device · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year to 40 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 17, 2026, 4:13 AM EDT
Active, not recruiting Not applicable Interventional

Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG

NCT03033992
View directory record Official record
Conditions
Malignant Glioma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Interventions
Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields), Concurrent Optune and RT followed by Optune System alone
Device · Combination Product
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 17, 2026, 4:13 AM EDT
Active, not recruiting Phase 2 Interventional

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

NCT02923778
View directory record Official record
Conditions
Leiomyosarcoma, Liposarcoma, Sarcoma G2, Sarcoma G3, Soft Tissue Sarcoma, Soft Tissue Sarcoma of the Trunk and Extremities, Stage I Soft Tissue Sarcoma AJCC v7, Stage II Soft Tissue Sarcoma AJCC v7, Undifferentiated Pleomorphic Sarcoma
Interventions
Biopsy Procedure, Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy, Talimogene Laherparepvec
Procedure · Radiation · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
16
States / cities
Phoenix, Arizona • Duarte, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 17, 2026, 4:13 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma

NCT02584829
View directory record Official record
Conditions
Merkel Cell Polyomavirus Infection, Stage IV Merkel Cell Carcinoma AJCC v7
Interventions
Avelumab, Laboratory Biomarker Analysis, MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells, Radiation Therapy, Recombinant Interferon Beta
Drug · Other · Biological + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Sep 17, 2026, 4:13 AM EDT
Recruiting Not applicable Interventional

Early Pelvic Floor Physical Therapy for Women Undergoing Pelvic Radiation for Gynecologic Malignancies

NCT07447895
View directory record Official record
Conditions
Cervical Cancer, Radiation Therapy Complication, Pelvic Floor Disorders
Interventions
Pelvic floor physical therapy
Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 17, 2026, 4:13 AM EDT
Not listed Phase 1 Interventional

CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme

NCT00768911
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
CT-322, Temozolomide, Radiation Therapy
Drug · Procedure
Lead sponsor
Adnexus, A Bristol-Myers Squibb R&D Company
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
6
States / cities
Little Rock, Arkansas • Chicago, Illinois • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2010 · Synced Sep 17, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Results available

Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer

NCT00288080
View directory record Official record
Conditions
Prostate Cancer
Interventions
Dexamethasone, Prednisone, docetaxel, Oral antiandrogen, Radiation therapy, LHRH agonist
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
245
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 194 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Sep 17, 2026, 4:13 AM EDT
Recruiting Phase 2 Interventional

FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery

NCT06780787
View directory record Official record
Conditions
Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions
Balstilimab, Biospecimen Collection, Botensilimab, Capecitabine, Computed Tomography, Digital Rectal Examination, Endoscopic Biopsy, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Oxaliplatin, Radiation Therapy, Sigmoidoscopy
Biological · Procedure · Drug + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 17, 2026, 4:13 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

NCT03914625
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome
Interventions
Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Mercaptopurine Oral Suspension, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
365 Days to 31 Years
Enrollment
6,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
201
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 17, 2026, 4:13 AM EDT
Recruiting Phase 2 Interventional

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

NCT04684368
View directory record Official record
Conditions
Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma, Immature Teratoma, Malignant Teratoma, Mixed Germ Cell Tumor, Pineal Region Germ Cell Tumor, Pineal Region Immature Teratoma, Pineal Region Yolk Sac Tumor, Suprasellar Germ Cell Tumor
Interventions
Biospecimen Collection, Carboplatin, Etoposide, Filgrastim, Ifosfamide, Magnetic Resonance Imaging, Mesna, Pegfilgrastim, Peripheral Blood Stem Cell Transplantation, Questionnaire Administration, Radiation Therapy, Second-Look Surgery, Thiotepa
Procedure · Drug · Biological + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 29 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
152
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 120 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 17, 2026, 4:13 AM EDT
Active, not recruiting Phase 1 Interventional

Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)

NCT04486755
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Hypofractionated Radiation Therapy
Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 17, 2026, 4:13 AM EDT
Recruiting Phase 3 Interventional

Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies

NCT07166042
View directory record Official record
Conditions
Breast Cancer, Gynecologic Cancer
Interventions
10-15 minute, Audio-Recorded Guided Mediation Practices
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 17, 2026, 4:13 AM EDT
Completed Phase 1 Interventional

Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer

NCT02903069
View directory record Official record
Conditions
Glioblastoma, Malignant Glioma
Interventions
MRZ, TMZ, RT, Optune
Drug · Radiation · Device
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
La Jolla, California • Orange, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Sep 17, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Results available

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

NCT00004054
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, estramustine phosphate sodium, etoposide, flutamide, paclitaxel, Luteinizing hormone releasing hormone [LHRH] agonist, Radiation therapy, warfarin
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Concord, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 17, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

NCT00070018
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, Cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, radiation therapy, Yttrium-90 ibritumomab tiuxetan, Indium-111 ibritumomab tiuxetan
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
48
States / cities
Anchorage, Alaska • Burbank, California • Boise, Idaho + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 17, 2026, 4:13 AM EDT
Completed Phase 2 Interventional

S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

NCT00005089
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
92
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2017 · Synced Sep 17, 2026, 4:13 AM EDT
Completed Phase 1Phase 2 Interventional

'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL

NCT04601831
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
Focal radiation therapy (RT)
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 17, 2026, 4:13 AM EDT
Recruiting Phase 2 Interventional

The University of Miami Adapt (UAdapt) Trial

NCT06111313
View directory record Official record
Conditions
Prostate Cancer
Interventions
FTLEAD, Ultra-Short-Term Androgen Deprivation Therapy with Relugolix, HypoLEAD, ADT Standard of Care
Radiation · Drug
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 85 Years · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 17, 2026, 4:13 AM EDT